SION
Sionna Therapeutics Inc
SION at a glance — five pillars scored 0–100 from real filed financials.
Overall: Unrated · 0/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Market Cap
$0.00
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
-24.0%
Interest Coverage
—
Current Ratio
22.6x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
0/100
Sionna Therapeutics Inc (SION) is a small-cap company in the Biotechnology industry, part of the Health Care sector of the S&P 500.
Our model rates SION Unrated (0/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
The case for SION:
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against SION:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Sionna Therapeutics Inc is a small-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Unrated (0/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
SION — frequently asked questions
Is SION a good stock to buy?
We don't give buy or sell advice. Review Sionna Therapeutics Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does SION's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Sionna Therapeutics Inc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for SION calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this SION analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell SION. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.